

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.” - HHS (again) postpones USPSTF meeting











